Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Accumulated Expenses (2016 - 2020)

Myriad Genetics (MYGN) has disclosed Other Accumulated Expenses for 7 consecutive years, with $22.4 million as the latest value for Q2 2020.

  • On a quarterly basis, Other Accumulated Expenses rose 24.44% to $22.4 million in Q2 2020 year-over-year; TTM through Jun 2020 was $22.4 million, a 24.44% increase, with the full-year FY2020 number at $22.4 million, up 24.44% from a year prior.
  • Other Accumulated Expenses was $22.4 million for Q2 2020 at Myriad Genetics, up from $4.3 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $22.4 million in Q2 2020 to a low of $4.3 million in Q1 2020.
  • A 5-year average of $13.8 million and a median of $14.0 million in 2017 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 84.81% in 2016, then tumbled 80.09% in 2020.
  • Myriad Genetics' Other Accumulated Expenses stood at $13.7 million in 2016, then grew by 13.87% to $15.6 million in 2017, then increased by 13.46% to $17.7 million in 2018, then crashed by 53.67% to $8.2 million in 2019, then skyrocketed by 173.17% to $22.4 million in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Other Accumulated Expenses are $22.4 million (Q2 2020), $4.3 million (Q1 2020), and $8.2 million (Q4 2019).